A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia Research Letter
| Authors: | Vasu, S.; Altman, J. K.; Uy, G. L.; Tallman, M. S.; Gojo, I.; Lozanski, G.; Burkard, U.; Osswald, A.; James, P.; Rüter, B.; Blum, W. |
| Title: | A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia |
| Keywords: | adult; controlled study; aged; unclassified drug; major clinical study; clinical trial; drug efficacy; drug safety; letter; progression free survival; apoptosis; phase 2 clinical trial; anemia; bone marrow; nausea; cytotoxicity; retrospective study; monoclonal antibody; alanine aminotransferase blood level; febrile neutropenia; alanine aminotransferase; aspartate aminotransferase; prednisolone; cd16 antigen; paracetamol; heart failure; immunogenicity; glucocorticoid; natural killer cell; leukocyte count; liver function test; phase 1 clinical trial; immunoglobulin g1; macrophage; phagocytosis; leukocytosis; brain hemorrhage; disease exacerbation; cd33 antigen; gemtuzumab ozogamicin; premedication; cd69 antigen; acute myeloid leukemia; lintuzumab; crystal; infusion related reaction; human; male; female; aspartate aminotransferase level; bi 836858 |
| Journal Title: | Haematologica |
| Volume: | 107 |
| Issue: | 3 |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2022-03-01 |
| Start Page: | 770 |
| End Page: | 773 |
| Language: | English |
| DOI: | 10.3324/haematol.2020.274118 |
| PUBMED: | 34854276 |
| PROVIDER: | scopus |
| PMCID: | PMC8883544 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 1 April 2022 -- Source: Scopus |
